5 Star Review

"Most helpful, steered us in the right direction for treatmen...." see more

Elaine C. - Mesothelioma Patient

5 Star Review

"Because of their guidance, I was able to navigate getting my...." see more

Deanna B. - Daughter of a Mesothelioma Patient

5 Star Review

"Hearing the news about my mother's diagnosis was heartbreaki...." see more

Danielle W. - Daughter of a Mesothelioma Patient

5 Star Review

"My son Carlos was diagnosed with this terrible and unknown d...." see more

Martha M. - Mother of a Mesothelioma Patient

5 Star Review

"Extremely communicative and helped my dad get an appointment...." see more

Sunni H. - Loved One of a Mesothelioma Patient

5 Star Review

"Danielle DiPietro was an invaluable resource for me. Her sug...." see more

Deborah C. - Spouse of a Mesothelioma Patient

5 Star Review

"I was very grateful and appreciative of Dr. Smart from The M...." see more

Kimberlin C. - Spouse of a Mesothelioma Patient

5 Star Review

"In January of 2016, my husband was diagnosed with peritoneal...." see more

Gloria R. - Spouse of a Mesothelioma Patient

Expertise:
Image-Guided Biopsies
Clinical Trials
Speciality:
Interventional Radiology
Gender:
Male
Language:
English, Hungarian

Primary Location

Moffitt Cancer Center

12902 Magnolia Drive, Tampa, FL 33612

Directions

He is currently the lead investigator in a groundbreaking phase II transarterial chemoperfusion clinical trial for patients with unresectable pleural mesothelioma.

It involves identifying specific blood vessels that feed the tumors, then overloading those vessels with high doses of specific chemotherapy agents to stop the cancer growth without exposing the rest of the body.

He is heavily involved with image guided tumor therapy, image-guided biopsies and urinary and biliary interventions, arterial and venous stenting. He also does minimally invasive percutaneous tumor ablation.

Kis came to Moffitt after completing radiology residency and interventional radiology fellowship at Brigham and Women’s Hospital, Harvard Medical School in Boston.

In 2020, Kis presented a novel mesothelioma treatment at the Society of Interventional Radiology’s Annual Scientific Meeting. He discussed the potential of transarterial chemoperfusion with cisplatin, methotrexate, and gemcitabine every four weeks as a feasible and safe treatment for patients with relapsed unresectable malignant pleural mesothelioma.

Dr. Kis’s clinical study of this new treatment resulted in a 70.3% disease control rate for patients with a median overall survival rate of 8.5 months. Patients reported that they tolerated the treatment well and that side effects were relatively minor such as mild nausea and chest pain.

“We were pleasantly surprised to find that this treatment doesn’t come with the same side effects of traditional intravenous chemotherapy,” said Kis during the virtual session. “To see these promising results with so few side effects means we are able to make a positive impact on quality of life for these patients.”

He holds a doctorate in cerebral microcirculation from University of Szeged in Hungary and did a post-doctoral fellowship and surgery internship at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina.